BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alborzinia H, Flórez AF, Kreth S, Brückner LM, Yildiz U, Gartlgruber M, Odoni DI, Poschet G, Garbowicz K, Shao C, Klein C, Meier J, Zeisberger P, Nadler-Holly M, Ziehm M, Paul F, Burhenne J, Bell E, Shaikhkarami M, Würth R, Stainczyk SA, Wecht EM, Kreth J, Büttner M, Ishaque N, Schlesner M, Nicke B, Stresemann C, Llamazares-Prada M, Reiling JH, Fischer M, Amit I, Selbach M, Herrmann C, Wölfl S, Henrich KO, Höfer T, Trumpp A, Westermann F. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. Nat Cancer 2022;3:471-85. [PMID: 35484422 DOI: 10.1038/s43018-022-00355-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Luo M, Yan J, Hu X, Li H, Li H, Liu Q, Chen Y, Zou Z. Targeting lipid metabolism for ferroptotic cancer therapy. Apoptosis 2022. [DOI: 10.1007/s10495-022-01795-0] [Reference Citation Analysis]
2 Dang Q, Sun Z, Wang Y, Wang L, Liu Z, Han X. Ferroptosis: a double-edged sword mediating immune tolerance of cancer. Cell Death Dis 2022;13:925. [PMID: 36335094 DOI: 10.1038/s41419-022-05384-6] [Reference Citation Analysis]
3 Chen J, Sun M, Chen C, Jiang B, Fang Y. Identification of hub genes and their correlation with infiltration of immune cells in MYCN positive neuroblastoma based on WGCNA and LASSO algorithm. Front Immunol 2022;13:1016683. [DOI: 10.3389/fimmu.2022.1016683] [Reference Citation Analysis]
4 Cornett K, Puderbaugh A, Back O, Craven R. GAPDH in neuroblastoma: Functions in metabolism and survival. Front Oncol 2022;12:979683. [DOI: 10.3389/fonc.2022.979683] [Reference Citation Analysis]
5 Qiao C, Wang H, Guan Q, Wei M, Li Z. Ferroptosis-based nano delivery systems targeted therapy for colorectal cancer: insights and future perspectives. Asian Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.ajps.2022.09.002] [Reference Citation Analysis]
6 Zhang J, Chen S, Wei S, Cheng S, Shi R, Zhao R, Zhang W, Zhang Q, Hua T, Feng D, Yu Z, Wang H. CircRAPGEF5 interacts with RBFOX2 to confer ferroptosis resistance by modulating alternative splicing of TFRC in endometrial cancer. Redox Biol 2022;57:102493. [PMID: 36182807 DOI: 10.1016/j.redox.2022.102493] [Reference Citation Analysis]
7 Dou J, Liu X, Yang L, Huang D, Tan X. Ferroptosis interaction with inflammatory microenvironments: Mechanism, biology, and treatment. Biomed Pharmacother 2022;155:113711. [PMID: 36126457 DOI: 10.1016/j.biopha.2022.113711] [Reference Citation Analysis]
8 Bartolucci D, Montemurro L, Raieli S, Lampis S, Pession A, Hrelia P, Tonelli R. MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment. Cancers 2022;14:4421. [DOI: 10.3390/cancers14184421] [Reference Citation Analysis]
9 He J, Wang X, Chen K, Zhang M, Wang J. The amino acid transporter SLC7A11-mediated crosstalk implicated in cancer therapy and the tumor microenvironment. Biochem Pharmacol 2022;205:115241. [PMID: 36084707 DOI: 10.1016/j.bcp.2022.115241] [Reference Citation Analysis]
10 Bansal M, Gupta A, Ding H. MYCN and Metabolic Reprogramming in Neuroblastoma. Cancers 2022;14:4113. [DOI: 10.3390/cancers14174113] [Reference Citation Analysis]
11 Dasgupta S, Gan B. Ferroptosis vulnerability in MYCN‐driven neuroblastomas. Clinical & Translational Med 2022;12. [DOI: 10.1002/ctm2.963] [Reference Citation Analysis]
12 Tan S, Kong Y, Xian Y, Gao P, Xu Y, Wei C, Lin P, Ye W, Li Z, Zhu X. The Mechanisms of Ferroptosis and the Applications in Tumor Treatment: Enemies or Friends? Front Mol Biosci 2022;9:938677. [DOI: 10.3389/fmolb.2022.938677] [Reference Citation Analysis]
13 Donati G, Nicoli P, Verrecchia A, Vallelonga V, Croci O, Rodighiero S, Audano M, Cassina L, Ghsein A, Binelli G, Boletta A, Mitro N, Amati B. Oxidative stress potentiates the therapeutic action of a mitochondrial complex I inhibitor in MYC-driven B-cell lymphoma.. [DOI: 10.1101/2022.06.21.497021] [Reference Citation Analysis]
14 Alborzinia H, Chen Z, Yildiz U, Freitas FP, Vogel FC, Varga J, Batani J, Bartenhagen C, Schmitz W, Büchel G, Michalke B, Zheng J, Meierjohann S, Girardi E, Espinet E, Florez A, dos Santos AF, Aroua N, Schlicker L, Xavier da Silva TN, Przybylla A, Zeisberger P, Superti-furga G, Eilers M, Conrad M, Fischer M, Schulze A, Trumpp A, Friedmann Angeli JP. Selenocysteine metabolism is a targetable vulnerability in MYCN-amplified cancers.. [DOI: 10.1101/2022.05.17.492172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Guan Q, Zhou L, Zhou W, Dong Y. A vinyl-decorated covalent organic framework for ferroptotic cancer therapy via visible-light-triggered cysteine depletion. J Mater Chem B 2022;10:8894-8909. [DOI: 10.1039/d2tb01815b] [Reference Citation Analysis]